Director Ashley Keating Sells Shares of Medpace Holdings Inc (MEDP)
Director Ashley Keating has executed a sale of 472 shares of Medpace Holdings Inc (NASDAQ:MEDP) on March 7, 2024, according to a recent SEC filing.Medpace Holdings Inc is a clinical contract research organization providing a full range of services to the pharmaceutical, biotechnology, and medical device industries. The company specializes in the strategic development, management, and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies.Ashley Keatings transaction history over the past year shows a total of 1,472 shares sold and no shares purchased. This latest transaction continues the trend of insider sales for the company.The insider transaction history for Medpace Holdings Inc indicates a pattern of insider selling, with 42 insider sells and no insider buys over the past year.
On the day of the insider's recent sale, shares of Medpace Holdings Inc were trading at $415, giving the company a market cap of $12.477 billion.The price-earnings ratio of Medpace Holdings Inc stands at 45.68, which is above the industry median of 29.23 and also exceeds the company's historical median price-earnings ratio.With the current share price of $415 and a GuruFocus Value of $327.11, Medpace Holdings Inc has a price-to-GF-Value ratio of 1.27, indicating that the stock is considered Modestly Overvalued according to the GF Value metric.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor related to past returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
